A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 7, 2012, Pages 879-881

  Messeguer, F ^a   Serra Guillen, C ^a   Echeverria, B ^a   Requena, C ^a   Sanmartin, O ^a   Llombart, B ^a   Guillen, C ^a   Nagore, E ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; LIQUID NITROGEN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CRYOTHERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; CRYOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SKIN NEOPLASMS;

EID: 84862776321     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04177.x     Document Type: Article

References (13)

1. Cohen JK,. Cryosurgery of the prostate: techniques and indications. Rev Urol 2004; 6 (Suppl 4): S20-26.
2. Gill IS, Remer EM, Hasan WA, et al. Renal cryoablation: outcome at 3 years. J Urol 2005; 173: 1903-1907. (Pubitemid 40675207)
3. Soanes WA, Ablin RJ, Gonder MJ,. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol 1970; 104: 154-159.
4. Joosten JJ, Muijen GN, Wobbes T, Ruers TJ,. In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology 2001; 42: 49-58. (Pubitemid 34169362)
5. Barrera MV, Herrera E,. Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives. Actas Dermosifiliogr 2007; 98: 556-562. (Pubitemid 47596711)
6. Redondo P, del Olmo J, Lopez-Diaz de Cerio A, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007; 127: 1673-1680. (Pubitemid 46933436)
7. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010; 9: 1101-1108.
8. Gaitanis G, Mitsou G, Tsiouri G, Alexis I, Bassukas ID,. Cryosurgery during imiquimod cream treatment ("immunocryosurgery") for Bowen's disease of the skin: a case series. Acta Derm Venereol 2010; 90: 533-534.
9. Gaitanis G, Nomikos K, Vava E, Alexopoulos EC, Bassukas ID,. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application. J Eur Acad Dermatol Venereol 2009; 23: 1427-1431.
10. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57: 616-621. (Pubitemid 47384927)
11. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733. (Pubitemid 38580549)
12. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-682.
13. Love WE, Bernhard JD, Bordeaux JS,. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-1438.